

INDEX

A

- Aerobic outgrowth.....201, 203, 212, 275, 276
- Anhydrotetracycline (atc) 152, 160, 183, 192
- Antibiotics
 - hygromycin 118–121, 132, 134–136, 156–161, 163, 165–170, 182, 188, 190, 195, 201, 372, 382, 390, 409
 - hygromycin resistance 119, 121, 134, 156–159, 161
 - kanamycin.....118–121, 128, 132, 135, 136, 158–160, 164–166, 169, 170, 172, 182, 187, 189–192, 195, 219, 221, 284, 288, 306, 372, 382, 390, 409
 - kanamycin resistance 119–121, 128, 136, 158
 - metronidazole 202, 283–285, 289, 294
- Arabinogalactan.....77, 78, 87
- ATP measurement
 - for antimicrobial susceptibility testing257–268
 - in non-replicating cells302, 312

B

- Biofilms
 - formation223, 225
 - role in drug tolerance215
 - role in persistence215, 216
- Bioinformatics 3, 10, 15, 19, 26
- Biomarkers47
- Biosafety Level 3 containment 10, 26, 111, 223, 236, 237, 367, 382

C

- cDNA
 - library22–23, 27
 - synthesis 32, 34–35, 38–39, 42
- Cell disruption
 - bead beater.....19, 20, 108, 111, 204, 208
 - French Press.....50, 56, 57, 68, 69, 71
- Cell wall
 - analysis.....48, 58, 77, 78, 83, 124, 227
 - bead assay for cell wall lipids.....357–367
 - composition77, 78
 - efflux.....227–239
 - extraction of lipids48, 78, 83
 - permeability77, 227–239
 - transport228
- Clumping 124, 127, 128, 168, 212, 308, 326, 336, 373, 388

- Colony forming units determination388
- Cord factor358
- Culture
 - anaerobic..... 202, 203, 206, 211, 212, 285, 289
 - clumping..... 124, 127, 128, 168, 212, 308, 326, 336, 373, 388
 - media 86, 113, 266
 - 96-well format216–218, 220, 224, 296, 299–302, 306–307, 320, 323
 - seed cultures..... 290, 335, 339, 363
 - 384-well format 296–298, 300, 301, 306
- Culture Filtrate
 - analysis..... 49, 54, 55, 70
 - components49–50
 - preparation.....54–55

D

- Dictyostelium discoideum369–384
- DNA
 - cDNA libraries7, 11, 22, 23, 27, 28, 32, 34, 41, 42
 - isolation of genomic DNA321, 324
 - paired-end sequencing.....12
 - single-end sequencing..... 11, 18, 19
 - strand-specific sequencing19, 43
- Drug resistance
 - antibiotic selection 121, 409
 - isolation of resistant mutants319, 322
 - MIC on solid medium..... 261, 264, 267, 318
 - whole genome sequencing179, 318

E

- Efflux
 - ethidium bromide 35, 36, 39, 44, 228, 232, 234–236, 238
 - inhibitors 228, 230–236, 238
 - measurement.....235
- Electroporation
 - arcng.....126, 128, 145, 194, 195
 - conditions123, 127
 - glycine treatment145
 - pre-treatment of DNA135, 138
 - recombination.....126
 - transformation efficiencies..... 117, 124, 146
- Electrospray ionization (ESI)-MS81

F

Fatty acids..... 78, 79, 82, 83, 87, 89, 97, 99
 Fluorescence
 microscopy.....388
 plate readers..... 229, 231, 362, 366
 reporter strains..... 242, 290, 330

G

Gene essentiality..... 134–136, 141–143, 164
 Gene expression..... 17, 23, 28, 29,
 31, 32, 151–153, 163, 169, 172, 242, 330
 Gene silencing. *See* Gene expression
 Genomic DNA
 preparation.....318, 319
 sequencing..... 7, 10, 42
 Glycerol monomycolate.....78, 98
 Glycopeptidolipids (GPL).....78, 82, 88, 90, 98, 99
 Growth analysis
 measuring ATP levels259
 measuring optical density205
 measuring oxygen consumption..... 211, 258–260, 264
 Growth analysis in liquid medium 161, 169–170
 Growth analysis on solid medium 146, 258, 318, 322
 Growth analysis using resazurin 258–261, 263, 267
 Growth inhibition
 measurement..... 172, 258, 265, 307
 models257

H

Headspace ratio225
 High content screening 388, 403–405
 High throughput screening216, 258, 282, 293–312, 388
 Hypoxia models
 anaerobic shiftdown..... 202, 206, 211, 212
 low oxygen recovery model.....281–290
 model of persistence201–212
 Rapid Anaerobic Dormancy (RAD) 202, 203, 206
 Wayne model.....201–203, 205, 210, 211, 294

I

Image analysis
 imageJ software.....373
 Inducible gene expression
 dual control.....155, 159–160, 163–164, 167
 generating conditional knockdowns165, 172
 inducer/promoter systems..... 151, 154, 155
 recombineering 158, 179, 183
 tetracycline controlled.....118, 120, 152, 159, 227
 Infection models
 dictyostelium discoideum369–384
 macrophages329–341
 PMNs..... 343–351, 353, 354

L

Lipids
 characterization77–101
 extraction 78, 83, 86, 87, 89, 93, 101
 isolation78, 97
 purification 81–85, 90–92, 97, 101
 Lipoarabinomannan (LAM) 78, 83,
 85–86, 93, 95–97, 101
 Low oxygen recovery assay (LORA)281–290
 Luminescence
 microscopy.....264, 265
 plate readers..... 205, 229, 362, 366
 reporter strains..... 242, 290, 330

M

Macrophage
 activation 295, 297, 331
 alveolar..... 344, 387
 bone marrow derived 329–337, 340, 389, 409
 in high-content screening293–312
 human monocyte derived THP-1.....409
 imaging..... 330, 332, 337
 infection model.....329–341
 models 329–340
 multiplicity of infection 219, 265, 349, 374, 388, 410
 murine J774329–331, 334, 336, 340
 phagosomes364
 viability272–274, 282, 294
 MALDI-ToF MS..... 48, 54, 67, 68, 73, 81, 82
 Media
 carbon source113, 228, 258, 278, 296, 297
 detergents 51, 59, 70, 73, 124
 dubos-tween-albumin.....203, 204
 growth 86, 308, 310
 middlebrook 7H9 86, 107, 120,
 124, 136, 138–143, 160, 181, 217, 218, 230, 236, 243,
 252, 260, 270, 282, 284, 288, 296, 319–321, 331, 335,
 346, 349, 353, 371
 middlebrook 7H10 108, 120, 136,
 139–142, 146, 160, 182, 183, 217, 261, 271, 318–320
 supplements.....296, 306
 tween 80 187, 191
 tyloxapol 107, 160, 297
 Metabolomics
 activity-Based Metabolomic Profiling (ABMP).....107
 carbon tracing107
 metabolite analysis..... 106, 107
 Microfluidics
 device fabrication.....244, 247
 microscopy.....241–255
 Minimal Inhibitory Concentration (MIC) determination
 growth readouts258
 intracellular MIC..... 261, 265, 357

in liquid medium 146, 161, 164, 165, 169, 170
 Microplate Alamar Blue Assay (MABA) 281–290
 on solid medium 122–124, 146, 160, 258, 261, 264, 267, 282, 284, 318–320, 322
 Minimum bactericidal concentration (MBC) 269, 270, 273–278
 Multi-stress non-replicating assay 294, 295
 Mycobacteriophages
 L5 attB integration site 134
 phage-mediated recombineering 155
 Mycobacterium avium 80, 88, 97, 98, 117–119, 123, 125, 126
 Mycobacterium leprae 82
 Mycobacterium marinum 369–384
 Mycobacterium smegmatis 151, 211, 216, 242, 260
 Mycobacterium tuberculosis 3, 10, 17–29, 32, 47, 79, 105–114, 117, 132, 177, 201, 216, 242, 257, 269–279, 281–290, 293–312, 317–327, 329–340, 343–354, 370, 387–410
 Mycobacterium ulcerans 82
 Mycolic acids (MA)
 mero-mycolic acid (mero-MA) 81
 mycolic acid methyl ester (MAME) 78, 79, 81, 84, 85, 87–90, 92, 93, 99, 100
 mycolic acyl chains 77

N

NADH/NAD
 measuring levels 202, 205, 209, 210, 213
 Nitrate reduction 204, 208
 Nitric oxide 212, 213, 295, 296, 311, 358
 Nitrite production
 measuring levels 204, 208
 Non-replicating persistence (NRP)
 hypoxia 201–213
 low pH 270, 278
 multi-stress 293–312
 nutrient starvation 271, 273
 Nontuberculous mycobacteria 48

O

Oxygen
 consumption 211, 258–260, 264
 depletion 210

P

Permeability 227–239, 318
 Phagocytosis 357, 358, 364, 369, 370, 374, 375, 383
 Phagosome
 bead phagosome 363
 prevention of acidification 387
 Phenolic glycolipids (PGL) 78, 81–83, 90, 98, 99
 Phosphatidyl inositol mannosides (PIM) 78, 82, 93, 98–100

Phthiocerol dimycocerosate (PDIM)
 analysis of transformants 136, 143
 in cell wall 78, 83
 virulence 132
 Polymorphonuclear neutrophils (PMN)
 growth/maintenance 353
 infection 350
 Promoter replacement
 gene silencing 154
 gene switching 132, 142
 homologous recombination 126, 131–148, 155, 369
 recombineering 155–158, 160, 162–165, 170, 177–197, 318, 327
 Protein
 ammonium sulfate partitioning 52, 53, 62, 70, 72
 analysis 47–73
 detergent extractions 48
 extraction 60
 fractionation 47–73
 Guanidine-HCl Dictyostelium
 discoideum 369–384
 hydrophilic 51, 52, 60, 62
 hydrophobic 48, 51–53, 60, 62, 64, 70, 93, 95, 228, 259
 Triton X-114 Partitioning 51, 60, 72
 Protein fractionation
 cell lysates 114
 sub-cellular fractionation 50, 57–59
 Protein Quantitations 55, 59, 62, 64, 66, 106
 Protein Separation
 hydrophobic interaction chromatography 53, 64, 93, 95
 iso-electric focusing 52, 63
 Proteolysis 56, 153, 154

R

Recombination
 homologous recombination 123, 131–148, 155, 369
 illegitimate recombination 132, 146, 178, 179
 marked mutations 146
 recombineering 155–158, 160, 162–165, 170, 177–197, 318, 327
 unmarked mutations 158, 161
 Recombineering
 lambda Red system 178
 phage-mediated 155
 promoter replacement 155, 160–162, 164–165, 171
 Reporter strains 242, 290, 330
 fluorescent 242, 330
 luminescent 330
 RNA
 extraction 43
 mapping transcriptional start sites 32
 sequencing 17, 31–44

S

Saponification..... 78, 81, 87, 96, 99
 Secreted proteins47
 Sequencing
 platforms..... 1, 2, 32
 reference genome.....2, 8, 17, 28, 32, 42
 resistant mutants139, 279, 318, 319, 322, 323, 325, 326
 transcriptional start sites31
 transcription start site mapping31–44
 transcriptome.....17–29
 whole genome..... 1–16, 318, 319, 324, 325, 327
 Single-cell analysis.....241–255
 Southern blot..... 139, 141, 142, 146, 161, 165, 167
 Suicide plasmids 145, 155, 177
 Sulfoglycolipids78, 83, 98

T

Time lapse microscopy 241–255, 375, 380
 Transcriptional regulation.....31, 154
 Transcriptome analysis17–29
 Transposon Library
 construction217, 218
 mapping insertion sites.....217
 screening.....217, 218, 224

Trehalose

 dimycolate (TDM) 82, 87, 88,
 90–92, 98, 100, 358–360, 363–367
 glycolipids.....78, 98, 99, 358, 363
 monomycolate (TMM)82, 87, 88, 90, 98, 100
 polyphthienoyl trehalose (PPT) 78, 81–83,
 87, 98, 100
 Triacylglycerol (TAG)78, 88, 90, 92, 98–100

V

Vectors

 episomal/replicating.....120, 146
 integrating120, 134, 136, 141, 146
 selectable markers 118, 119, 133
 UV pretreatment.....145

Viability

 measurement..... 273, 274, 347, 353
 models203, 352, 353

W

Whole Genome Sequencing1–15
 data analysis.....4, 8–9
 DNA isolation321, 324–325
 RNA isolation.....204, 208